Novo Nordisk

Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.

Roche to buy 89bio for up to $3.5 billion in obesity push

Roche is seeking to catch up with Novo Nordisk A/S and Eli Lilly & Co., makers of multibillion-dollar blockbusters Wegovy and Zepbound

How Novo Nordisk lost its lead in the weight loss race

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors

Novo Nordisk launches blockbuster weight loss drug Wegovy in India

The drug will follow a four-week cycle for dosage, starting with the smallest dose of 0.25 mg per week for four weeks, followed by a gradual increase in dosage.

Activist hedge fund Parvus builds stake in Novo Nordisk as leadership search begins

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

Novo preparing for early launch of weight-loss drug Wegovy in India

Novo and Lilly have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers to among the world's most valuable companies.

Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

Divis Lab: GLP-1 opportunity to unfold in the medium term

Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.

Novo Nordisk falls most on record after new weight drug disappoints

The shot helped patients lose an average of 20.4% of their weight over 68 weeks, short of the 25% weight loss that Novo had predicted for its next-generation product, which analysts had expected to launch in 2026.

Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms: Report

More recently, Novo's India team proposed moving the launch to next year, around the same time Lilly is expected to introduce its weight-loss drug Mounjaro.

Biocon’s formulations business to outpace API share soon: CEO

Formulations will focus on peptides, a class of drugs that among other things hels in weight loss, said the MD and CEO

Dr Reddy’s: Watchful of the Revlimid cliff

In times to come, the company may gear up for new inorganic initiatives to improve its market share in India. In the meantime, margins may moderate

Riding on Novo Nordisk’s semaglutide, India’s weight-loss market triples in size in 2 years

Semgalutide has almost 66 percent of the market share in the anti-obesity segment.

Novo Nordisk's parent invests in India's Manipal hospital chain

"It (the investment) represents our commitment towards filling the gap between the enormous demand and underserved healthcare infrastructure in India," Novo Holdings said in a statement.

Popular weight-loss drugs like Wegovy may raise risk of complications under anaesthesia

Some anesthesiologists in the US and Canada say they've seen growing numbers of patients on the weight-loss drugs who inhaled food and liquid into their lungs while sedated because their stomachs were still full even after following standard instructions to stop eating for six to eight hours in advance.

All you need to know about Mounjaro, the antidiabetic injectable also touted as the most powerful weight-loss drug ever

The availability of the drug in India may cause a major disruption in the Indian diabetes care drugs market which is expected to register a CAGR greater than 3.5 percent between 2022 and 2027. The COVID-19 pandemic has contributed a major increase in the market.

Efforts on to launch once-a week- insulin in India by mid-2025: Novo Nordisk MD

Danish pharma giant working on launching Icodec. India managing director and corporate vice-president Vikrant Shrotriya says the company also has a plan to launch anti-obesity drug, Wegovy, in India but it may not happen very soon.

Fat-busting diabetes drug is a global smash hit but remains prohibitively pricey for many Indians

Tesla and Twitter owner Elon Musk is the latest celebrity to admit using Wegovy, a higher dose version of Ozempic, for keeping his body "fit, ripped, and healthy”. The drug has caused quite a stir among celebs and influencers over the last several months

Novo Nordisk, Roche partner to enhance Type 1 Diabetes care for children in India

This partnership is part of a global collaboration that will impact around 4,000 children with Type 1 diabetes in India.

Smart insulin is the future: Vikrant Shrotriya of Novo Nordisk

If taking an insulin injection every day is difficult for a diabetes patient, a once-a-week option would probably be more acceptable in the future.

Novo Nordisk joins hands with AMR Action Fund to fight antimicrobial resistance

The fund aims to bring 2-4 new antibiotics to market this decade that will save patients' lives.

Novo Nordisk names Vikrant Shrotriya as new India head

Shrotriya has over 20 years of experience in the healthcare industry.

Novo Nordisk remains on the hunt for biopharma deals

France's Sanofi won Ablynx and its prized experimental bleeding disorder drug caplacizumab with a 50 percent higher bid than the previously rejected offer from Novo Nordisk.

Drugmaker Novo Nordisk bets $145 mn on post-Brexit UK science

The Danish company said on Monday it would invest the money over 10 years in the centre based at the University of Oxford, which will employ 100 scientists hunting for new ways to treat type 2 diabetes.

Novo Nordisk says to cut 1,000 jobs

"This is one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market," the Denmark-based company said in a statement.